Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 8 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Kidney Metabolic

Heart Failure
Eco 25: The SURMOUNT-1 Study
Author(s): Luca Busetto Added: 11 months ago
ECO 2025 - Three-year findings of tirzepatide treatment, a GIP/GLP-1 agonist, for patients with prediabetes observed stable weight loss results and suggests that tirzepatide is a viable option for patients with indication. The study also observed the total weight loss patients may obtain can be predicted within the first month of treatment with tirzepatide.Prof Luca Busetto (Padova University… View more

Cardiovascular Kidney Metabolic
Obesity & Weight Management Alliance Conference 2025
Start date: Mar 07, 2025 End date: Mar 07, 2025
Obesity & Weight Management Alliance Conference 2025 will take place on March 7th 2025 in London at Thistle London Marble Arch. View more
International Conference on Diabetes, Obesity and Metabolic Diseases 2025
Start date: Feb 01, 2025 End date: Feb 02, 2025
ICDOMD - 2025 will take place from February 1st to February 2nd 2025 in Geneva at Bernina Hotel Geneva. View more
Healthful Nutrition, Physical Activity, Behaviour Modification and MDT
Author(s): Erin D Michos , Ozden Gokdemir , Lydia Alexander , et al Added: 1 year ago
In this third session of Advancements in Obesity Management (AOM) 2024, the panel explore the biological,environmental,psychologicaland social factors contributing to obesity. View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Angela Fitch
Research Area(s) / Expertise: Job title: Chief Medical Officer and Co-Founder of knownwell
Dr Angela Fitch, MD, FACP, MFOMA is the past president of the Obesity Medicine Association. She practiced primary care for 10 years before becoming a diplomate of the American Board of Obesity Medicine in 2012. She is currently the Chief Medical Officer and Co-Founder of knownwell, a comprehensive longitudinal obesity treatment and primary care clinic focused on delivering unbiased non… View more
Medical and Procedural Options and the Referral Pathways
Author(s): Harold Bays , Francesco Rubino , Alexander Miras Added: 1 year ago
In the final session of Advancements in Obesity Management (AOM) 2024, the panel discuss practical considerations in utilising new pharmacological therapies for treating obesity and cover the extensive development pipeline. The current understanding of clinical outcome data and patient referral criteria are also discussed for surgical approaches. View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
HFSA 2025 Late-Breaking Science Collection
Author(s): Nir Uriel Added: 6 months ago
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Society of America's annual congress, HFSA 2025.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators. View more

Cardiovascular Kidney Metabolic

Guidelines & Statements
ADA 25: Efficacy and Safety of CagriSema in REDEFINE 1 and 2
Author(s): Sue Pedersen Added: 9 months ago
ADA 25 - CagriSema shows benefits in obesity and type 2 diabetes in the REDEFINE 1 and 2 trials.In this video, we are joined by Dr Sue Pedersen (C-endo Diabetes and Endocrinology Clinic, Calgary, CA) to discuss the findings from the REDEFINE 1 and 2 trials which investigated the effect of CagriSema 2.4mg.Findings showed that CagriSema was associated with weight reduction efficacy across patients… View more

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Director of the Obesity, Metabolism & Nutrition Institute
Dr Lee Kaplan is Director of the Obesity, Metabolism & Nutrition Institute, founding director of the Weight Center at the Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School. Dr Kaplan's clinical expertise is in the areas of obesity medicine, gastroenterology and liver disease. The author of more than 150 medical and scientific papers, he has a special… View more